Florbetaben F 18 injection(with Chinese trademark 欧韦宁®), an early diagnostic tool for Alzheimer’s disease, has been officially launched in hospitals across China, achieving GMP-standardized production and commercialization.

• Meilleur, an overseas affiliate, and its next-generation Aβ-PET imaging agent NAV-4694 for Alzheimer’s disease, have been acquired by the Nasdaq-listed company Lantheus.
• Jiangsu Sinotau Pharmaceutical Co., Ltd., a subsidiary, has obtained a radioactive drug business license.
• Sichuan Sinotau Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the Radiation Safety License.
• Sinotau is awarded the national “Specialized, Refined, and New ‘Little Giant’” enterprise title, highlighting our innovation capabilities and market competitiveness.

• Adenosine injection (with Chinese trademark欧达乐^®) was approved for marketing.
• Nasdaq-listed company Lantheus acquired Cerveau, a joint venture of Sinotau.
• Closed a CNY ¥1.1bn financing round and the total financing amounts to CNY ¥2.6bn.
• Florbetaben F 18 injection（with Chinese trademark 欧韦宁^® and foreign trademark Neuraceq^® was received regulatory approval from National Medical Products Administration (NMPA) in China, which is the first domestic radiopharmaceutical targeting β-amyloid approved to be used to support diagnosis of Alzheimer’s disease (AD).

• XTR006, an ¹⁸F-labeled PET imaging agent with a high-affinity to Tau protein developed for Alzheimer’s disease, received clinical approval.
• The New Drug Application of Florbetaben F 18 injection was being accepted.
• The first subject had been dosed in the Phase III clinical trial of lutetium Lu 177 dotatate, which is the first domestic targeted therapeutic radiopharmaceutical independently developed by Sinotau, on Sept.24, 2022.
• Clinical trial application of [¹⁷⁷Lu]Lu-XT033 injection was approved.
• The single-photon emission computed tomography(SPECT) machine received registration certificate for medical device, becoming the first large professional equipment in the field of Chinese cardiac nuclear medicine to promote domestic production.

• Completed clinical trial of Neuraceq^TM.
• Completed Phase I clinical trial of XTR003 and XTR004, and initiated Phase II clinical trial.
• Closed CNY ¥640m series D&D+ financing round co-invested by CICC, China Life Private Equity, Centurium Capital and many other well-known investment institutions.
• Achieve strategic collaboration with Biogen, JOINN, United Imaging, DualityBio respectively.

• Obtained clinical trial approval of class 1 new drugs XTR003 and XTR004.
• Closed CNY ¥640m series D&D+ financing round co-invested by Hynergy Industrial Funds Management Co., Ltd., Sinopharm Capital, Lotus Lake Captital, Cash Capital and Winning Ventures.

• Obtained clinical trial approval of Neuraceq^TM.

• Obtained global authorization for a new drug for nuclear therapy of prostate cancer from the National Institutes of Health (NIH).

• Entered into a licensing agreement with Cerveau Technologies, Inc. for the rights to a Tau protein tracer in China.
• Entered into a licensing agreement with Piramal Imaging SA for the rights to beta amyloid tracer Neuraceq^TM in China.
• Closed a CNY ¥150m series B financing round co-invested by Qiming Venture Partners and 3E Bioventures.

• Established Cerveau, a US joint venture.
• Closed a CNY ¥130m series A financing round led by Winning Ventures.

• Sinotau USA Inc., a wholly owned subsidiary of Sinotau, was established in Boston.

• Started the research and development of radiopharmaceuticals.